Rapid expansion of preexisting nonleukemic hematopoietic clones frequently follows induction therapy for de novo AML.
about
DNMT3A and TET2 in the Pre-Leukemic Phase of Hematopoietic DisordersMeasurable residual disease testing in acute myeloid leukaemia.Clonal evolution in myelodysplastic syndromesTP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic SyndromesPreleukemia: one name, many meanings.Molecular and genetic alterations associated with therapy resistance and relapse of acute myeloid leukemia.Precision and prognostic value of clone-specific minimal residual disease in acute myeloid leukemia.Acute Myeloid Leukemia: How Do We Measure Success?Spontaneous Remission in an Older Patient with Relapsed FLT3 ITD Mutant AML.Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia.CHIP, ICUS, CCUS and other four-letter words.Ultrasensitive mutation detection identifies rare residual cells causing acute myelogenous leukemia relapse.Genomics of primary chemoresistance and remission induction failure in paediatric and adult acute myeloid leukaemia.Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic workup and therapy.The Prognostic Significance of Measurable ("Minimal") Residual Disease in Acute Myeloid Leukemia.Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential.Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia.Patient-tailored analysis of minimal residual disease in acute myeloid leukemia using next-generation sequencing.Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy.'CHIP'ping away at clonal hematopoiesis.When to obtain genomic data in acute myeloid leukemia (AML) and which mutations matter
P2860
Q28073970-3D0B9F51-E8A3-45CB-A5B2-7C78D5050D96Q30234914-00DF6D60-2B80-4BDF-A496-A130F14F36A9Q34555597-BD79B44E-6F4D-4226-AD17-9680A90EC9FAQ37566878-C0FD4BB3-1538-4EF2-BDE7-5C9D3DF65A04Q37683379-177C6615-AB45-48CF-B509-9728327629F6Q38755213-5EAC462D-F487-4DEE-A51D-DC1D4E007E1BQ38902497-9CDB3D04-A650-4ABB-9BB7-37E4D0568829Q38948650-9630FA85-26CA-44E5-9E73-6540B54A97EFQ39105964-B8BEF7F2-1D5C-44D8-B40F-A66BF5557425Q39132424-3ADB8AEF-FEB4-49CD-A635-1B6169E48D9CQ39358533-484E9BA5-F4FE-41CF-B3FC-2348CC98A970Q40497621-4E1FE9B4-67BB-48D3-AD2B-FA9E5DE1E11DQ40526958-EB9B9284-0D12-4562-8CC7-9C076EBF4084Q44176860-9582E355-BE71-4600-BF7C-3418A4C363C7Q47804815-FF20EDC9-DB4B-417C-BA5D-BC36A8E0F832Q49200018-3833DD51-4C3D-4AC8-B214-FAF960512401Q50001759-92F1423A-CBCF-4AA8-949E-D931F1228F97Q50642627-9EF90A9B-9B27-43DC-AC2E-573FFDD692CBQ52803473-05E85CC1-6FC4-4A33-96B9-EFD1686F3B68Q52863785-F5E8CEB2-5C5B-49BA-9066-961FB238CE29Q59133388-CCF15F05-9EDF-4F82-A700-CC4255BDEB69
P2860
Rapid expansion of preexisting nonleukemic hematopoietic clones frequently follows induction therapy for de novo AML.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Rapid expansion of preexisting ...... ction therapy for de novo AML.
@ast
Rapid expansion of preexisting ...... ction therapy for de novo AML.
@en
type
label
Rapid expansion of preexisting ...... ction therapy for de novo AML.
@ast
Rapid expansion of preexisting ...... ction therapy for de novo AML.
@en
prefLabel
Rapid expansion of preexisting ...... ction therapy for de novo AML.
@ast
Rapid expansion of preexisting ...... ction therapy for de novo AML.
@en
P2093
P2860
P50
P1433
P1476
Rapid expansion of preexisting ...... uction therapy for de novo AML
@en
P2093
Allegra Petti
Daniel C Link
Jeffery M Klco
John F DiPersio
John S Welch
Nichole M Helton
Peter Westervelt
Richard K Wilson
Robert S Fulton
Ryan Demeter
P2860
P304
P356
10.1182/BLOOD-2015-10-677021
P407
P577
2015-12-02T00:00:00Z